Bellerophon Therapeutics, Inc. (BLPH)
| Previous Close | 1.7900 |
| Open | 1.7500 |
| Bid | 1.9100 x 3000 |
| Ask | 1.9300 x 1400 |
| Day's Range | 1.7400 - 1.9350 |
| 52 Week Range | 0.6700 - 3.5000 |
| Volume | |
| Avg. Volume | 1,090,521 |
| Market Cap | 18.136M |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8850 |
| Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.50 |
- GlobeNewswire
Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023WARREN, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment
- Simply Wall St.
Companies Like Bellerophon Therapeutics (NASDAQ:BLPH) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater ChinaWARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences compa
